Funding Opportunities

 This is a listing of Requests for Applications (RFA), Program Announcements (PA), and Notices specific to the group's key programs.

Standard submission dates apply for all listings, unless otherwise noted.

Guidance For Investigators Planning to Submit a Program Project Grant (P01)

Notice: Internet links not permitted in NIH Grant Applications

Information about the funding opportunity announcements that align with the efforts of the Cancer MoonshotSM can be found here: https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/funding.

Title Announcement # Expiration Date Research Focus
Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems PAR-20-155 (R01 Clinical Trial Optional) 09/08/2022
    • Cancer Biomarkers
Administrative Supplement for Research on Dietary Supplements (Admin Supp-Clinical Trial Not Allowed) PA-20-227 04/16/2023
    • Nutritional Science
Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research RFA-CA-21-006 (R33 Clinical Trial Not Allowed) 09/30/2021
    • Cancer Biomarkers
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research RFA-CA-21-004 (R33 Clinical Trial Not Allowed) 09/29/2021
    • Cancer Biomarkers
Advanced Development of Informatics Technologies for Cancer Research and Management RFA-CA-21-015 (U24 Clinical Trial Optional) 11/18/2021
    • Cancer Biomarkers
Assay Validation of High Quality Markers for Clinical Studies in Cancer PAR-20-314 (UH3 Clinical Trials Not Allowed) 10/11/2023
    • Cancer Biomarkers
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed) PAR-20-313 10/11/2023
    • Cancer Biomarkers
Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention PAR-19-252 (R21 Clinical Trial Optional) 11/09/2021
    • Cancer Biomarkers
Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention PAR-19-251 (R01 Clinical Trial Optional) 11/09/2021
    • Cancer Biomarkers
Basic Research in Cancer Health Disparities PAR-21-322 (R01 Clinical Trial Not Allowed) 09/08/2024
    • Gastrointestinal and Other Cancers
Basic Research in Cancer Health Disparities PAR-21-324 (R03 Clinical Trial Not Allowed) 09/08/2024
    • Gastrointestinal and Other Cancers
Basic Research in Cancer Health Disparities PAR-21-323 (R21 Clinical Trial Not Allowed) 09/08/2024
    • Gastrointestinal and Other Cancers
Biology of Bladder Cancer PAR-19-183 (R01 Clinical Trial Optional) 05/08/2022
    • Prostate and Urologic Cancer
Biology of Bladder Cancer PAR-19-184 (R21 Clinical Trial Optional) 05/08/2022
    • Prostate and Urologic Cancer
Cancer Prevention and Control Clinical Trials Grant Program PAR-21-035 (R01 Clinical Trial Required) 01/08/2024
    • Breast and Gynecologic Cancer
Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Centers RFA-CA-21-038 (U54 Clinical Trial Not Allowed) 10/08/2021
    • Cancer Prevention-Interception Targeted Agent Discovery Program
Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Data and Resource Coordination Center (CAP-IT DRCC) RFA-CA-21-039 (U24 Clinical Trial Not Allowed) 10/08/2021
    • Cancer Prevention-Interception Targeted Agent Discovery Program
Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research PAR-19-113 (R01 Clinical Trial Optional) 01/08/2022
    • Cancer Biomarkers
Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies PAR-19-325 (R01 Clinical Trial Optional) 02/12/2022
    • Supportive Care and Symptom Management
    • Community Oncology and Prevention Trials
Co-infection and Cancer PAR-20-062 (R01 Clinical Trial Not Allowed) 01/08/2023
    • Cancer Biomarkers
Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management RFA-CA-21-013 (R21 Clinical Trial Optional) 11/18/2021
    • Cancer Biomarkers
Early-Stage Development of Informatics Technologies for Cancer Research and Management RFA-CA-21-014 (U01 Clinical Trial Optional) 11/18/2021
    • Cancer Biomarkers
Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer PAR-19-264 (R01 Clinical Trial Optional) 12/11/2021
    • Consortium for Imaging and Biomarkers
    • Cancer Biomarkers
Improving Outcomes in Cancer Treatment-Related Cardiotoxicity PA-19-111 (R21 Clinical Trial Optional) 01/08/2022
    • Supportive Care and Symptom Management
Improving Outcomes in Cancer Treatment-Related Cardiotoxicity PA-19-112 (R01 Clinical Trial Optional) 01/08/2022
    • Supportive Care and Symptom Management
Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research RFA-CA-21-005 (R21 Clinical Trial Not Allowed) 09/30/2021
    • Cancer Biomarkers
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research RFA-CA-21-003 (R21 Clinical Trial Not Allowed) 09/30/2021
    • Cancer Biomarkers
Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R01- Clinical Trial Not Allowed) PAR-20-088 04/02/2022
    • Cancer Biomarkers
Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R21- Clinical Trial Not Allowed) PAR-20-081 04/02/2022
    • Cancer Biomarkers
Mechanisms that Impact Cancer Risk after Bariatric Surgery PAR-21-332 (R21 Clinical Trial Not Allowed) 09/08/2024
    • Breast and Gynecologic Cancer
Mechanisms that Impact Cancer Risk after Bariatric Surgery PAR-21-331 (R01 Clinical Trial Optional) 09/08/2024
    • Breast and Gynecologic Cancer
Mechanisms Underlying the Contribution of Sleep Disturbances to Pain PA-19-200 (R01 Clinical Trial Optional) 05/08/2022
    • Supportive Care and Symptom Management
Mechanisms Underlying the Contribution of Sleep Disturbances to Pain PA-19-201 (R21 Clinical Trial Optional) 05/08/2022
    • Supportive Care and Symptom Management
Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer PAR-19-198 (R01 Clinical Trial Not Allowed) 11/09/2021
    • Nutritional Science
Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer PAR-19-199 (R21 Clinical Trial Not Allowed) 11/09/2021
    • Nutritional Science
Music and Health: Understanding And Developing Music Medicine PAR-21-100 (R01 Clinical Trial Optional) 02/06/2023
    • Supportive Care and Symptom Management
Music and Health: Understanding And Developing Music Medicine PAR-21-099 (R21 Clinical Trial Optional) 02/17/2023
    • Supportive Care and Symptom Management
NCI Clinical and Translational Exploratory/Developmental Studies PAR-20-292 (R21 Clinical Trial Optional) 07/21/2022
    • Breast and Gynecologic Cancer
Notice of Correction to Application Types Allowed for PAR-20-053, Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection NOT-CA-20-067 (R01 Clinical Trial Not Allowed) 01/08/2023
    • Cancer Biomarkers
Notice of Intent to Publish a Funding Opportunity Announcement for Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network NOT-CA-21-114 (UG1 Clinical Trial Required) 08/01/2022
    • Breast and Gynecologic Cancer
Notice of Intent to Publish a Funding Opportunity Announcement for Coordinating Center for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network NOT-CA-21-112 (U24 Clinical Trial Required) 08/01/2022
    • Breast and Gynecologic Cancer
Notice of Intent to Publish a Funding Opportunity Announcement for Mechanisms that Impact Cancer Risk after Bariatric Surgery NOT-CA-21-091 (R21 Clinical Trial Not Allowed) 11/01/2021
    • Breast and Gynecologic Cancer
Notice of Intent to Publish a Funding Opportunity Announcement for Mechanisms that Impact Cancer Risk after Bariatric Surgery NOT-CA-21-090 (R01 Clinical Trial Optional) 11/01/2021
    • Breast and Gynecologic Cancer
Notice of Intent to Publish a Funding Opportunity Announcement for Research Bases for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network NOT-CA-21-113 (UG1 Clinical Trial Required) 08/01/2022
    • Breast and Gynecologic Cancer
Notice of Special Interest: Advancing the Science of Geriatric Palliative Care NOT-AG-20-041 09/08/2023
    • Supportive Care and Symptom Management
    • Community Oncology and Prevention Trials
Notice of Special Interest: Development of Swallowable Smart Pills or Devices for Precision Nutrition, Microbiome and Digestive Disease Applications NOT-DK-20-001 01/08/2023
    • Nutritional Science
Notice of Special Interest: National Cancer Institute Administrative Supplement Opportunity for Strategies to Optimize Recruitment and Retention of Cancer Prevention and Symptom Management Clinical Trial Participants NOT-CA-21-070 05/16/2023
    • Gastrointestinal and Other Cancers
Notice of Special Interest (NOSI): Advancing Head and Neck Cancer Early Detection Research (AHEAD) NOT-CA-20-031 01/08/2022
    • Cancer Biomarkers
Notice of Special Interest (NOSI): Biology of Lung and Head and Neck Preneoplasia NOT-CA-21-057 05/08/2023
    • Lung and Upper Aerodigestive Cancer
Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers NOT-CA-21-028 01/08/2024
    • Cancer Biomarkers
    • Gastrointestinal and Other Cancers
Notice of Special Interest (NOSI): Single-Cell Proteomics for Interrogating Premalignant and Early Malignant Lesions NOT-CA-20-044 05/08/2023
    • Cancer Biomarkers
Notice of Special Interest: Small Business Development of Wearable Smart Devices for Continuous Monitoring of Circulating Nutrients, Metabolites and Hormones NOT-DK-20-002 01/08/2023
    • Nutritional Science
Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit PAR-21-335 (U24 Clinical Trial Not Allowed) 06/12/2024
    • Pancreatic Cancer Detection Consortium
    • Cancer Biomarkers
Pancreatic Cancer Detection Consortium: Research Units PAR-21-334 (U01 Clinical Trial Optional) 06/12/2024
    • Pancreatic Cancer Detection Consortium
    • Cancer Biomarkers
Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection PAR-20-053 (R01 Clinical Trial Not Allowed) 01/08/2023
    • Cancer Biomarkers
Promoting Research on Music and Health: Phased Innovation Award for Music Interventions (R61/R33 Clinical Trial Optional) PAR-20-266 06/20/2023
    • Supportive Care and Symptom Management
Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants PAR-20-074 (R01 Clinical Trial Not Allowed) 10/29/2022
    • Gastrointestinal and Other Cancers
Revision Applications to Support the Application of Informatics Technology for Cancer Research RFA-CA-21-017 (R01 Clinical Trials Optional) 11/18/2021
    • Cancer Biomarkers
Revision Applications to Support the Application of Informatics Technology for Cancer Research RFA-CA-21-019 (U24 Clinical Trial Optional) 11/19/2021
    • Cancer Biomarkers
Revision Applications to Support the Application of Informatics Technology for Cancer Research RFA-CA-21-018 (U01 Clinical Trials Optional) 11/18/2021
    • Cancer Biomarkers
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes PAR-20-276 (R01 Clinical Trial Not Allowed) 09/08/2022
    • Cancer Biomarkers
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes PAR-20-277 (R21 Clinical Trials Not Allowed) 09/08/2022
    • Cancer Biomarkers
Stephen I. Katz Early Stage Investigator Research Project Grant PAR-21-039 (R01 Basic Experimental Studies with Humans Required) 12/29/2023
    • All DCP Research Groups
Stephen I. Katz Early Stage Investigator Research Project Grant PAR-21-038 (R01 Clinical Trial Not Allowed) 12/29/2023
    • All DCP Research Groups
Sustained Support for Informatics Technologies for Cancer Research and Management RFA-CA-21-016 (U24 Clinical Trial Optional) 11/18/2021
    • Cancer Biomarkers
Translational and Basic Science Research in Early Lesions (TBEL) RFA-CA-21-054 (U54 Clinical Trial Not Allowed) 11/03/2021
    • Cancer Biomarkers
Translational and Basic Science Research in Early Lesions (TBEL) Coordinating and Data Management Center RFA-CA-21-055 (U24 Clinical Trial Not Allowed) 11/03/2021
    • Cancer Biomarkers
Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research PAR-21-330 (U01 Clinical Trial Not Allowed) 10/12/2024
    • Early Detection
Validation Studies of Analytical Methods for Dietary Supplement Constituents (Admin Supp - Clinical Trial Not Allowed) PA-20-252 04/16/2022
    • Nutritional Science